INTRODUCTION
Copper naphthenate (CAS# 1338-02-9) is a fungicide used as a wood preservative. Very few cases of toxicity have been reported in the literature. In this case, persistently elevated serum copper levels were thought to be due to a woman's exposure to the fumes of copper naphthenate. She remained asymptomatic without end organ injury, and serum copper levels were later shown to be due to the physiologic effect of her oral contraceptive. This case also shows the value of RBC copper levels in assessing copper toxicity risk.
CASE REPORT
A previously healthy 44-year-old Caucasian female was exposed to fumes from copper naphthenate applied to wood beams in her home bathroom by a termite removal contractor. This was in the form of a wood preservative, comprised of 15% copper naphthenate, 50% process oil, and 35% mineral spirits. In spite of attempts to ventilate the material out the bathroom window with a fan, the patient still noted a strong turpentine-type odor throughout the home. She indicated that the container label recommended outside use only. She noted nausea, nasal congestion, and headache, but no associated cough, runny nose, or eye irritation. Her husband had no symptoms, but he slept further from the bathroom area than his wife; they had no children or pets.
She was seen in the local emergency department; no significant clinical findings were noted and no tests were done. The poison control center was consulted. Avoidance and ventilation of the home was recommended. The odor in the home persisted, and a "wood remediation" sealant was applied. Subsequently, the odor dissipated over 3 weeks. Five weeks after the initial exposure, the patient saw her primary doctor; at that time she was asymptomatic, but serum copper was elevated to 1500 g/L (24 mol/L) (normal 800-1300 g/L, performed by a certified laboratory, analysis by flame atomic absorption spectroscopy).
A heavy metal blood panel was obtained with normal values (arsenic Ͻ10 g/L, mercury Ͻ4 g/L, lead Ͻ3 g/dL). These tests were repeated and were normal 1 month later, but serum copper remained elevated at 2055 g/L (32 mol/L) (normal 490-1840 g/L), performed by another certified laboratory, analysis by flame atomic absorption spectroscopy). She remained asymptomatic at 6 months post-exposure, but serum copper was still elevated at 2301 g/L (36 mol/L) (normal 490-1840 g/L).
A comprehensive metabolic panel was obtained and was normal, including liver function testing. An industrial medicine specialist saw her at 7 months. CBC and comprehensive panel were normal, but serum copper remained elevated at 2003 g/L (36 mol/L) (normal 490-1840 g/L). Toxicology consultation was recommended.
The patient was seen in consultation by this author, a boardcertified medical toxicologist, at 9 months post-exposure. She remained asymptomatic, was living in the same home, and had no other significant changes since the exposure. Her husband had never been ill, but lab testing on him at 1 and 2 months post-exposure was said to be normal (documents not available to the author). There was no other significant exposure for copper. Water pipes in the home were thought to be copper, but the patient drank commercial bottled water. Medications included: Wellbutrin 150 mg/day, Omega 3 fatty acid, Flaxseed, and Yasmin (drospirenone and ethinyl estradiol) oral contraceptive. She was taking no vitamins and had not used a copper IUD, copper bracelets or copper-based ointments. Past medical history was remarkable for prior shoulder rotator cuff surgery, bilateral foot surgery, and sinus surgery. There was a history of hay fever to pollen and mold, with sporadic sinus headaches. She used occasional alcohol, but did not smoke or use street drugs. Review of systems was unremarkable. She rarely used insecticides in the garden, but no copper agents. Family and social history were noncontributory. She was an administrative analyst at a university with no chemical exposure. Physical exam was unremarkable, including no Kayser-Fleischer rings in the cornea. CBC, comprehensive panel, serum iron studies, sedimentation rate, CRP, TSH, rheumatoid factor and ANA were normal. Serum copper was 1930 g/L (30 mol/L) (normal 800-1550 g/L, performed by third certified laboratory, analysis by inductively coupled plasma/mass spectrometry); ceruloplasmin was 49 mg/dL (normal 17-54).
Subsequently, RBC copper was obtained and was normal at 0.65 mg/L (10 mol/L) (normal range 0.53-0.77 mg/L) and a 24-hour urine copper was 2.3 g/dL (0.36 mol/L) (normal 0.2-8.0 g/dL); simultaneous serum copper remained elevated at 2284 g/L (36 mol/L) (normal 490-1840 g/L).
A low copper diet was instituted; chelation was not recommended. Subsequently, on further literature review an estrogen effect was suspected and the low copper diet was discontinued. The patient agreed to stop her oral contraceptive for 2 months and repeat lab tests. Subsequently, 11 months post-exposure, serum copper was normal at 1331 g/L (21 mol/L) (normal 490-1840 g/L), with an RBC copper of 0.49 mg/L (7.7 mol/L) (normal 0.53-0.77 mg/L). The serum copper level represented a 30% reduction from prior levels; the slightly low RBC copper result was not thought to be significant. Hormone levels were not obtained.
DISCUSSION
Copper toxicity from copper naphthenate has previously been reported in the literature, but is rare. The first case was reported in 1992 in a family of three (all women, ages 18, 21, and 44 years) where copper naphthenate was sprayed on the inner foundation of a home.
They reported nausea, vomiting, burning of the eyes, dizziness, and headache. Two of the individuals had elevated serum copper levels; one (the mother) was followed over several years and had gradual decline in serum and urine copper levels. For example, serum levels declined from 2250 g/L (35 mol/L)at 14 months post-exposure to 1800 g/L (28 mol/L) at 41 months (normal 750-1450 g/L). It was not known if "symptoms reflected exposure to naphthenate, the solvent vehicle, volatized copper, or the stress of the exposure to a malodorous compound perceived as toxic." It was noted that volatility of the chemical was moderately low, although no air levels were ever measured. Chelation therapy was not performed. RBC copper levels were not done and medications were not listed. As noted in the article, "The interpretation of copper levels regarded as 'normal' or 'toxic' after copper naphthenate exposure is, however, uncertain and requires additional study for clarification." [1] A 1999 abstract from the San Francisco poison center reported on a case of elevated serum copper and methemoglobinemia from residential exposure to copper naphthenate. A family of five (41-year-old male, 40-year-old female and three children aged 2, 3, and 5 years) was exposed to copper naphthenate sprayed heavily on the hardwood floor of their home. Symptoms included headache, dizziness, nausea and fatigue. An initial methemoglobin level was 16% in the mother; following ventilation and shutting off the heater it was 0.9% at 12 days. Serum copper levels were reported as 1000 g/L (16 mol/L) in the father, 1450 g/L (23 mol/L) in the mother; 1650 (26 mol/L) in the 5-year-old, 2000 (31 mol/L) in the 3-year-old, and 2200 (35 mol/L) in the 2-year-old (normal 650-1450 g/L).
No RBC copper levels were reported, nor was medication use. The family moved out of the house, but no repeat levels were done [2] . Elevations in serum copper have been reported in various anemias, including iron deficiency, leukemia, infection, lymphoma, biliary cirrhosis, hemochromatosis, collagen diseases, thyroid disorders, pregnancy and ingestion of oral contraceptives/estrogens, and Wilson's disease [3] . Hinks reported on copper concentrations in leukocytes and erythrocytes and the effect of estrogens in 1983 [4] . Whole blood was obtained from 119 normal healthy volunteers: 55 men aged 18-63 years and 64 women aged 21-57 years. Twenty-two of the women were taking a combination oral contraceptive ("the pill," ethinyloestradiol 30 g and levonorgestrel 150 g). No hormone levels were reported.
Reference ranges for copper were derived from cumulative frequency distribution curves. Plasma copper reference range varied from 12.5-21.0 mol/L for women off the pill to 15.5-29.5 on the pill (where mol/L ϫ 63.5 = g/L). Measured plasma copper for women off the pill averaged 16.7 ± 2.8 mol/L, while those on the pill averaged 24.3 ± 3.7 mol/L. RBC copper for those off the pill was 1.11 ± 0.16 picamol/10 6 cells and for those on the pill 1.17 ± 0.21 picamol/10 6 cells. Thus, significant increases in plasma copper concentrations were noted in women taking oral contraceptives "and these findings are consistent with previous reports." It was thought that the increase was a result of increased synthesis of ceruloplasmin in response to estrogen, but the metabolic balance of copper was not altered. "It was noted that no significant increase was found in the copper content of leucocytes or erythrocytes in the group of women taking oral contraceptives." Hinks also noted: "The analysis of leucocytes may reflect more accurately acute changes in zinc and copper status as these are metabolically active and have a shorter life span than erythrocytes, and because they (unlike erythrocytes) are nucleated, they are more likely to be representative of other cells. Additionally, Baselt has noted: "In a study of 48 cases of acute (usually intentional) copper sulfate poisoning, it was found that blood {pre-sumed RBC} copper levels correlated well with the severity of intoxication, whereas serum levels did not" [5] .
Also, Goodhart noted that serum copper is increased in a number of conditions (vide supra), but "In general the concentration in red blood cells is unaffected" [6] . According to the Expert Group on Vitamins and Minerals: "Acute copper toxicity in humans is rare due to the emetic properties and unpleasant taste of the compounds. There are relatively few data on lower level or chronic oral copper exposure in man. Copper is kept under tight homeostatic control to prevent the accumulation of excess amounts.
Where dietary copper is high, absorption is reduced and, in particular, biliary excretion is increased. Other mechanisms, which sequester excess copper within the cell, may also occur. Copper toxicity occurs when such defenses are overwhelmed. Thus, in man, liver toxicity has only been seen in genetically determined conditions such as Wilson's disease and in Indian Childhood Cirrhosis where hepatic copper accumulation occurs." [7] In this case, there was no clear evidence of any of the underlying disease processes associated with elevated serum copper levels. Additionally, except for a brief period following her exposure to the copper naphthenate fumes, she had no symptoms or evidence of end organ injury once her exposure ceased. The persistent elevation of serum copper months after the initial exposure suggested a non-toxic or laboratory effect, which was most consistent with the effect seen with estrogen intake. Removal of exogenous estrogen resulted in a normalization of the serum copper, without a significant effect on RBC copper (although it was slightly lower than normal). In retrospect, the estrogen effect on serum copper resulted in about a 30% increase from the patient's normal range. It is not known if this would be comparable for other women taking exogenous estrogen, although this was approximately the same range of increase seen in the cases reported by Hinks.
CONCLUSION
Although exposure to copper naphthenate has the potential to raise serum levels of copper, it is not known if RBC copper levels would be affected, as no cases until now have ever been tested. At least in this case, such an exposure led to repeated measurements of serum copper in an asymptomatic patient, later shown to be due to exogenous ingestion of estrogen for birth control as a normal physiologic effect. Copper naphthenate toxicity would appear to be an unlikely event in this case. This case reaffirms the importance of thorough history taking and evaluating all potential sources of elevated serum copper levels. Toxicologists should consider measurement of RBC copper levels as a better indicator of toxicity risk when faced with clinical exposures to excess copper.
